Abcellera Biologics/$ABCL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abcellera Biologics
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Ticker
$ABCL
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Vancouver, Canada
Employees
596
ISIN
CA00288U1066
Website
ABCL Metrics
BasicAdvanced
$1B
-
-$0.57
0.46
-
Price and volume
Market cap
$1B
Beta
0.46
52-week high
$3.68
52-week low
$1.89
Average daily volume
5.7M
Financial strength
Current ratio
10.146
Quick ratio
8.558
Long term debt to equity
6.179
Total debt to equity
6.179
Profitability
EBITDA (TTM)
-231.196
Gross margin (TTM)
-637.51%
Net profit margin (TTM)
-726.26%
Operating margin (TTM)
-1,256.95%
Effective tax rate (TTM)
20.30%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-12.94%
Return on equity (TTM)
-15.59%
Valuation
Price to revenue (TTM)
44.373
Price to book
1.01
Price to tangible book (TTM)
1.11
Price to free cash flow (TTM)
-7.158
Free cash flow yield (TTM)
-13.97%
Free cash flow per share (TTM)
-48.48%
Growth
Revenue change (TTM)
-35.41%
Earnings per share change (TTM)
11.32%
3-year revenue growth (CAGR)
-63.84%
3-year earnings per share growth (CAGR)
-3.93%
What the Analysts think about ABCL
Analyst ratings (Buy, Hold, Sell) for Abcellera Biologics stock.
Bulls say / Bears say
AbCellera's expansion of its collaboration with AbbVie to develop novel T-cell engagers for oncology enhances its pipeline and potential revenue streams. (abcellera.com)
The company advanced two internal programs into IND-enabling studies, with Phase 1 trials expected to start in Canada in the second half of 2025, indicating progress towards clinical-stage development. (biospace.com)
AbCellera maintains a strong liquidity position with $633 million in cash, cash equivalents, and marketable securities, providing a projected runway of over 36 months to support its strategic initiatives. (biospace.com)
AbCellera reported a 57% year-over-year decline in total revenue to $4.2 million for Q1 2025, primarily due to a 58% drop in research fees, signaling potential challenges in partner platform adoption. (biospace.com)
The company's net loss widened by 12.3% to $45.6 million in Q1 2025 compared to the same period in 2024, reflecting increased operating expenses amid declining revenue. (biospace.com)
AbCellera's reliance on partnerships for revenue, with no marketed proprietary products and no significant recurring revenue expected until additional programs are secured, poses a risk to its financial stability. (assetroom.net)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
ABCL Financial Performance
Revenues and expenses
ABCL Earnings Performance
Company profitability
ABCL News
AllArticlesVideos
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575
Business Wire·3 weeks ago
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause
Business Wire·1 month ago
AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abcellera Biologics stock?
Abcellera Biologics (ABCL) has a market cap of $1B as of June 20, 2025.
What is the P/E ratio for Abcellera Biologics stock?
The price to earnings (P/E) ratio for Abcellera Biologics (ABCL) stock is 0 as of June 20, 2025.
Does Abcellera Biologics stock pay dividends?
No, Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Abcellera Biologics dividend payment date?
Abcellera Biologics (ABCL) stock does not pay dividends to its shareholders.
What is the beta indicator for Abcellera Biologics?
Abcellera Biologics (ABCL) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.